
Nifty Pharma Prediction for Tomorrow: F&O Levels and Outlook for 23 June 2026
Nifty Pharma closed 24,762.90 on 22 June 2026, +1.24%. Prev close 24,460.30. Nifty 50 24,102.90. VIX 27.32. Futures 24,790.
Updated: 22 Jun 2026 • 4:39 pm
Posted by:

The nifty pharma prediction for tomorrow for 23 June 2026 is shaped by today's close at 24,762.90 (+302.60, +1.24% from 24,460.30), a +positive session driven by strong US generics demand and domestic formulation volume growth driving pharma outperformance. The broader Nifty 50 closed at 24,102.90 (+0.37%) while India VIX rose to 27.32, reflecting elevated near-term uncertainty ahead of the Nifty 50 weekly expiry on 23 June 2026.
Ankit Jaiswal, Senior Research Analyst at Univest, and Associate Director Kunal Singla have analysed today's Nifty Pharma price action, F&O data, and sector-specific triggers to present the nifty pharma prediction for tomorrow. Their analysis covers key support and resistance levels, futures positioning, and the broader market backdrop for Tuesday's session.
Click Here – Get Free Investment Predictions
Nifty Pharma Prediction for Tomorrow: Today's Close Summary
- Close and Change: Nifty Pharma settled at 24,762.90 on 22 June 2026, moving +302.60 (+1.24%) from the previous close of 24,460.30. Nifty Pharma surged +1.24%, the top performer among sector indices today, on domestic formulation growth and improving US generic exports.
- F&O Snapshot: Nifty Pharma futures closed at 24,790 with a ~27 pts premium premium over spot. No direct Nifty Pharma F&O expiry on Tuesday. Intraday high was 25,000 and low was 24,300.
- Broader Market: Nifty 50 (+0.37%), Bank Nifty (+0.43%), and most sector indices ended positive on 22 June 2026, supported by Iran-US peace talk optimism and recovering IT sector (+0.74%).
Nifty Pharma Prediction for Tomorrow: Technical Analysis
Trend: Cautiously Bullish | Key Range: 24,500 to 25,000
| Level | Nifty Pharma |
|---|---|
| Support 1 | 24,500 |
| Support 2 | 24,300 |
| Resistance 1 | 25,000 |
| Resistance 2 | 25,200 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
The nifty pharma prediction for tomorrow from Ankit Jaiswal places 24,500 as the immediate support for Tuesday. A hold above this level keeps the near-term bias constructive and targets 25,000 as the first upside objective. A decisive break above 25,000 with volume would open the path toward 25,200. On the downside, a breach of 24,500 would expose 24,300 as the next support. Jaiswal notes Nifty Pharma's +1.24% gain today is the strongest sector performance and the nifty pharma prediction for tomorrow is bullish above 24,500 support. The sector has been in a consistent uptrend.
Nifty Pharma F&O Analysis for 23 June 2026
- Futures Close: Nifty Pharma futures closed at 24,790 on 22 June 2026, maintaining a ~27 pts premium premium. The nifty pharma prediction for tomorrow is underpinned by this positive carry signal.
- Nifty 50 Expiry Context: Tuesday 23 June 2026 is the Nifty 50 weekly expiry (moved to Tuesdays since September 2025). Broad market volatility from expiry will affect the nifty pharma prediction for tomorrow in the first and final trading hours.
- VIX Impact: India VIX at 27.32 signals elevated near-term volatility. Sector indices including Nifty Pharma tend to exhibit wider intraday ranges when VIX is elevated on an expiry day.
Global and Macro Cues for Nifty Pharma Prediction for Tomorrow
- Iran-US Talks: Day 2 of negotiations in Switzerland is the key macro event. A breakthrough would broadly lift Indian equities and specifically benefit Nifty Pharma via improved investor sentiment and potential FII reversal.
- US Markets: S&P 500 (+1.09%), Nasdaq (+1.91%) provided a positive overnight base. GIFT Nifty at ~24,120 signals a positive pre-open for Tuesday that should support Nifty Pharma.
- DII Support: DIIs net bought Rs 3,516 crore on 18 June, providing structural support that prevents panic selling even on FII pressure days. This backstop is positive for the nifty pharma prediction for tomorrow.
Screen Nifty Pharma Stocks Before Tuesday's Open on Univest
Trading Strategy Based on Nifty Pharma Prediction for Tomorrow
- Long Setup: The nifty pharma prediction for tomorrow suggests buying on dips to 24,500 with stop at 24,300 and initial target at 25,000. Use the broader Nifty 50 expiry session confirmation before entering.
- Breakout Play: A sustained move above 25,000 with volume confirms the nifty pharma prediction for tomorrow bullish case. Target 25,200 with stop at 24,500.
- Expiry Caution: Nifty 50 expiry volatility on Tuesday can drag sector indices. The nifty pharma prediction for tomorrow advises waiting for 10:00 AM before committing to directional positions.
- Position Sizing: VIX at 27.32 warrants reduced leverage. The nifty pharma prediction for tomorrow recommends half-normal position sizes for the expiry session.
What OI and Flow Data Indicate for the nifty pharma prediction for tomorrow
FII net selling of Rs 47,903 crore MTD in June has been fully absorbed by DII buying of Rs 66,215 crore MTD. This net flow dynamic is positive for the nifty pharma prediction for tomorrow and suggests institutional demand is keeping the index supported even on days of foreign selling pressure.
Kunal Singla notes that Nifty Pharma futures premium of ~27 pts premium reflects positive carry positioning for Tuesday. A compression of this premium intraday on Tuesday would signal that sellers are becoming active at current levels and would be an early warning for the nifty pharma prediction for tomorrow outlook.
Download the Univest iOS App or Univest Android App to get live Nifty Pharma updates and expert research.
Risks to the nifty pharma prediction for tomorrow
- Iran Talks Collapse: An overnight breakdown in Switzerland would trigger broad risk-off, dragging the nifty pharma prediction for tomorrow below 24,500 on a gap-down open for Tuesday.
- Nifty Expiry Shock: An unexpected Nifty 50 expiry outcome could create cross-sector volatility that temporarily breaks the nifty pharma prediction for tomorrow's support levels.
- US FDA Action: Import alerts or warning letters from USFDA for major pharma manufacturers would sharply pressure the nifty pharma prediction for tomorrow below 24,500.
- FII Selling: If Monday provisional FII data shows outflows above Rs 2,000 crore, it dampens the opening tone for the nifty pharma prediction for tomorrow despite positive global cues.
Conclusion
In summary, the nifty pharma prediction for tomorrow on 23 June 2026 is cautiously positive with 24,500 as the critical support and 25,000 as the key resistance. Ankit Jaiswal notes that a hold above 24,500 with positive global cues from Iran-US talks would keep the nifty pharma prediction for tomorrow constructively bullish. The nifty pharma prediction for tomorrow turns decisively positive only on a sustained break above 25,000.
This nifty pharma prediction for tomorrow is based on market data as of close of trade on 22 June 2026. Track GIFT Nifty before 9:15 AM and monitor the Nifty 50 expiry volatility for real-time confirmation of the nifty pharma prediction for tomorrow direction on 23 June 2026.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs
What is the nifty pharma prediction for tomorrow?
Ans. The nifty pharma prediction for tomorrow on 23 June 2026 is cautiously bullish with support at 24,500 and resistance at 25,000. Nifty Pharma closed at 24,762.90 on 22 June 2026, +302.60 (+1.24%). Watch GIFT Nifty and Iran-US talks outcome before the 9:15 AM open.
What is the Nifty Pharma support and resistance for 23 June 2026?
Ans. Ankit Jaiswal places Nifty Pharma support at 24,500 and 24,300 for 23 June 2026. Resistance levels are 25,000 and 25,200. A sustained break above 25,000 with volume would confirm the nifty pharma prediction for tomorrow bullish outlook for Tuesday.
How does Nifty 50 expiry affect the Nifty Pharma Tuesday view?
Ans. The Nifty 50 weekly expiry on 23 June 2026 adds cross-index volatility to the Nifty Pharma Tuesday view. Broad selling on expiry day could drag Nifty Pharma below 24,500. A smooth expiry supports the Nifty Pharma Tuesday view positive bias and allows for cleaner sector-level directional trades.
What global cues affect the Nifty Pharma Tuesday view?
Ans. GIFT Nifty at 24,120, Iran-US talks in Switzerland, and S&P 500 (+1.09%) are the key global inputs for the Nifty Pharma Tuesday view. A positive Iran-US outcome overnight would boost the Nifty Pharma Tuesday view via improved FII flow and risk-on sentiment for Tuesday.
What is the F&O strategy from the Nifty Pharma Tuesday view?
Ans. The Nifty Pharma Tuesday view suggests buying dips to 24,500 with stop at 24,300 and target at 25,000. For a breakout above 25,000, the Nifty Pharma Tuesday view targets 25,200. Reduce position size given VIX at 27.32 and Nifty 50 expiry volatility on 23 June 2026.
Recent Articles

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
28 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Popular this week
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





